A Phase 3 interventional study of Placebo and Upadacitinib in Rheumatoid Arthritis, sponsored by AbbVie. Completed at 188 sites in 27 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-02-08.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 5th largest by enrollment, is one of 4 that started in 2016, is one of 7 in phase 3, and was the 6th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18–65
AbbVie
Ages 18+
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 8 · Phase 4 3
First in 2012; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 499 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 300 across the 19 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 7th largest by enrollment of the 38 interventional ones that give a count, is one of 7 that started in 2016, is one of 11 in phase 3, and was the 53rd registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, from their registry updates:
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The study objective of Period 1 (Day 1 to Week 24) is to compare the safety and efficacy of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of participants with moderately to severely active rheumatoid arthritis (RA) who are on a stable dose of csDMARDs and had an inadequate response to or intolerance to at least 1 bDMARD.
The study objective of Period 2 (Week 24 to Week 260) is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants with RA who completed Period 1.
This study includes a 35-day screening period; a 24-week randomized, double-blind, parallel-group, placebo controlled treatment period (Period 1); a 236-week blinded long-term extension period (Period 2); and a 30-day follow-up period (call or visit).
Period 1 consists of a 12-week double-blind, placebo-controlled treatment phase plus a 12-week double-blind phase where all participants were to receive upadacitinib; at Week 12 participants assigned to placebo will be switched to upadacitinib according to their randomization assignment.
Participants who meet eligibility criteria will be randomized in a 2:2:1:1 ratio to one of four treatment groups:
Participants will continue stable dose of csDMARD therapy for the first 24 weeks of the study.
Participants who complete the Week 24 visit (end of Period 1) will enter the blinded long-term extension portion of the study, Period 2 and continue to receive the same dose of upadacitinib per original randomization assignment in a blinded manner. Starting at Week 24, at least 20% improvement in both swollen joint count (SJC) and tender joint count (TJC) compared to Baseline is required to remain on study drug. Starting at Week 24, initiation of or change in corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or adding or increasing doses in up to 2 csDMARDs (concomitant use of up to 2 csDMARDs except the combination of methotrexate and leflunomide) is allowed as per local label.
With the implementation of Protocol Amendment 4, all participants in the extension period will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Period 1: Participants receive upadacitinib 15 mg once daily for 24 weeks. Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260.
Drug: Upadacitinib
Period 1: Participants receive upadacitinib 30 mg once daily for 24 weeks. Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260.
Drug: Upadacitinib
Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 15 mg once daily for 12 weeks. Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260.
Drug: Placebo · Drug: Upadacitinib
Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 30 mg once daily for 12 weeks. Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260.
Drug: Placebo · Drug: Upadacitinib
Tablet; Oral
Tablet; Oral
Also known as: ABT-494, RINVOQ®
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 12. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.
Time frame: Week 12
Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline in DAS28 (CRP) indicates improvement in disease activity.
Time frame: Baseline and Week 12
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and week 1
Participants were enrolled at 152 sites located in 26 countries from March 2016 to January 2017. Eligible participants had active rheumatoid arthritis (RA) and previous inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (bDMARDs), and were receiving concomitant background conventional synthetic DMARDS (csDMARDs).
| Milestone | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Started | 85 | 84 | 165 | 165 |
| Received study treatment | 85 | 84 | 164 | 165 |
| Completed | 75 | 76 | 157 | 149 |
| Not completed | 10 | 8 | 8 | 16 |
| Withdrew: Adverse event | 2 | 2 | 1 | 12 |
| Withdrew: Withdrawal by subject | 2 | 1 | 4 | 2 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 0 |
| Withdrew: Other | 4 | 4 | 2 | 2 |
| Withdrew: Randomized in error | 0 | 0 | 1 | 0 |
| Milestone | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Started | 75 | 76 | 157 | 149 |
| Received study treatment | 72 | 75 | 156 | 148 |
| Completed | 72 | 74 | 153 | 135 |
| Not completed | 3 | 2 | 4 | 14 |
| Withdrew: Adverse event | 1 | 2 | 2 | 5 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Other | 1 | 0 | 1 | 4 |
| Milestone | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Started | 71 | 73 | 152 | 132 |
| Switched to upadacitinib 15 mg after protocol amendment 4 | 0 | 44 | 0 | 94 |
| Completed | 35 | 41 | 81 | 82 |
| Not completed | 36 | 32 | 71 | 50 |
| Withdrew: Adverse event | 11 | 9 | 21 | 11 |
| Withdrew: Withdrawal by subject | 11 | 10 | 17 | 10 |
| Withdrew: Lost to follow-up | 1 | 5 | 9 | 6 |
| Withdrew: Lack of efficacy | 5 | 3 | 9 | 8 |
| Withdrew: Other | 8 | 5 | 15 | 15 |
The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | 28.4 (21.6 to 35.2) | 64.6 (57.3 to 72.0) | 56.4 (48.8 to 63.9) |
The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 12. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 | 14.2 (8.9 to 19.5) | 43.3 (35.7 to 50.9) | 42.4 (34.9 to 50.0) |
The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline in DAS28 (CRP) indicates improvement in disease activity.
| units on a scale | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12 | -1.02 (-1.23 to -0.80) | -2.31 (-2.52 to -2.10) | -2.29 (-2.50 to -2.09) |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
| units on a scale | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 | -0.17 (-0.26 to -0.08) | -0.39 (-0.48 to -0.30) | -0.42 (-0.51 to -0.33) |
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.
| units on a scale | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12 | 2.39 (1.14 to 3.64) | 5.83 (4.60 to 7.05) | 7.02 (5.78 to 8.25) |
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | 11.8 (7.0 to 16.7) | 34.1 (26.9 to 41.4) | 35.8 (28.4 to 43.1) |
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | 6.5 (2.8 to 10.2) | 11.6 (6.7 to 16.5) | 23.0 (16.6 to 29.5) |
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1 | 10.7 (6.0 to 15.3) | 27.4 (20.6 to 34.3) | 24.8 (18.3 to 31.4) |
Collected over Adverse events are reported for Weeks 1 to 12 (all participants) and from Weeks 1 to 260 for participants who received upadacitinib.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo: Weeks 1-12 | 0/169 (0%) | 0/169 (0%) | 68/169 (40.2%) |
| Upadacitinib 15 mg: Weeks 1-12 | 0/164 (0%) | 9/164 (5.5%) | 68/164 (41.5%) |
| Upadacitinib 30 mg: Weeks 1-12 | 1/165 (0.6%) | 12/165 (7.3%) | 78/165 (47.3%) |
| Upadacitinib 15 mg: Weeks 1-260 | 9/236 (3.8%) | 87/236 (36.9%) | 196/236 (83.1%) |
| Upadacitinib 30 mg: Weeks 1-260/Switch | 5/240 (2.1%) | 71/240 (29.6%) | 203/240 (84.6%) |
| Upadacitinib 15 mg After Switch | 2/138 (1.4%) | 21/138 (15.2%) | 59/138 (42.8%) |
| Event | Placebo: Weeks 1-12 | Upadacitinib 15 mg: Weeks 1-12 | Upadacitinib 30 mg: Weeks 1-12 | Upadacitinib 15 mg: Weeks 1-260 | Upadacitinib 30 mg: Weeks 1-260/Switch | Upadacitinib 15 mg After Switch |
|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/169 | 0/164 | 2/165 | 5/236 | 9/240 | 1/138 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/169 | 1/164 | 1/165 | 7/236 | 3/240 | 1/138 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/169 | 1/164 | 0/165 | 5/236 | 7/240 | 2/138 |
| Deep vein thrombosisVascular disorders | 0/169 | 0/164 | 0/165 | 5/236 | 1/240 | 1/138 |
| Acute myocardial infarctionCardiac disorders | 0/169 | 0/164 | 0/165 | 4/236 | 1/240 | 0/138 |
| COVID-19Infections and infestations | 0/169 | 0/164 | 0/165 | 4/236 | 1/240 | 2/138 |
| COVID-19 pneumoniaInfections and infestations | 0/169 | 0/164 | 0/165 | 3/236 | 0/240 | 2/138 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/169 | 0/164 | 0/165 | 2/236 | 0/240 | 2/138 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/169 | 1/164 | 0/165 | 3/236 | 0/240 | 0/138 |
| VomitingGastrointestinal disorders | 0/169 | 0/164 | 0/165 | 0/236 | 3/240 | 0/138 |
| Event | Placebo: Weeks 1-12 | Upadacitinib 15 mg: Weeks 1-12 | Upadacitinib 30 mg: Weeks 1-12 | Upadacitinib 15 mg: Weeks 1-260 | Upadacitinib 30 mg: Weeks 1-260/Switch | Upadacitinib 15 mg After Switch |
|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 13/169 | 13/164 | 11/165 | 74/236 | 67/240 | 1/138 |
| Urinary tract infectionInfections and infestations | 10/169 | 16/164 | 9/165 | 43/236 | 49/240 | 11/138 |
| NasopharyngitisInfections and infestations | 11/169 | 7/164 | 9/165 | 34/236 | 41/240 | 3/138 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 10/169 | 4/164 | 6/165 | 34/236 | 39/240 | 13/138 |
| BronchitisInfections and infestations | 4/169 | 7/164 | 4/165 | 27/236 | 37/240 | 0/138 |
| Herpes zosterInfections and infestations | 1/169 | 2/164 | 2/165 | 22/236 | 32/240 | 8/138 |
| HypertensionVascular disorders | 4/169 | 3/164 | 3/165 | 29/236 | 19/240 | 3/138 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/169 | 4/164 | 3/165 | 28/236 | 19/240 | 3/138 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/169 | 1/164 | 2/165 | 26/236 | 28/240 | 4/138 |
| Blood creatine phosphokinase increasedInvestigations | 0/169 | 2/164 | 3/165 | 18/236 | 27/240 | 4/138 |
The full analysis set (FAS) included all randomized participants who received at least 1 dose of study drug. The 2 placebo groups were combined for analysis of data through Week 12.
| Age, Continuous(years) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Mean | 57.6 ± 11.39 | 56.3 ± 11.34 | 57.3 ± 11.55 | 57.1 ± 11.42 |
| Age, Customized(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| < 40 years | 14 | 11 | 14 | 39 |
| 40 - 64 years | 106 | 115 | 103 | 324 |
| ≥ 65 years | 49 | 38 | 48 | 135 |
| Sex: Female, Male(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Female | 143 | 137 | 138 | 418 |
| Male | 26 | 27 | 27 | 80 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 24 | 34 | 28 | 86 |
| Not Hispanic or Latino | 145 | 130 | 137 | 412 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| White | 143 | 142 | 148 | 433 |
| Black or African American | 21 | 17 | 10 | 48 |
| American Indian/Alaska Native | 0 | 3 | 4 | 7 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 1 | 1 |
| Asian | 5 | 2 | 2 | 9 |
| Geographic Region(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| North America | 110 | 109 | 109 | 328 |
| Western Europe | 33 | 32 | 32 | 97 |
| Eastern Europe | 23 | 22 | 22 | 67 |
| Asia | 0 | 0 | 1 | 1 |
| Other | 3 | 1 | 1 | 5 |
| Prior Failed Biological Disease-modifying Anti-rheumatic Drugs (bDMARDs)(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Stratum 1 | 117 | 116 | 111 | 344 |
| Stratum 2 | 52 | 48 | 54 | 154 |
| Duration of RA Diagnosis(years) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Mean | 14.5 ± 9.22 | 12.4 ± 9.38 | 12.7 ± 9.65 | 13.2 ± 9.45 |
9 further baseline measures are reported on the registry.
Showing the first 100 of 188 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: For details on when studies are available for sharing, please refer to the link below.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · vivli.org
Ran from Mar 2016 to primary completion in Apr 2017, 12 months.
Results were first posted in Oct 2019, 2 years 6 months after primary completion. A results delay was requested in Feb 2018.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 12 months is below that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib